Shandong Keyuan Pharmaceutical Co. Ltd. A Total Liabilities

Latest as of June 2025: CN¥222.24 Million CNY ≈ $32.52 Million USD

Shandong Keyuan Pharmaceutical Co. Ltd. A total liabilities. Based on the latest financial reports, Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has total liabilities worth CN¥222.24 Million CNY (≈ $32.52 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Shandong Keyuan Pharmaceutical Co. Ltd. to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)

Total liabilities of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024. This chart illustrates how Shandong Keyuan Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.

Shandong Keyuan Pharmaceutical Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Shandong Keyuan Pharmaceutical Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
MTY Food Group Inc
TO:MTY
Canada CA$1.67 Billion
Beijing SPC Environment Protection Tech Co Ltd
SHE:002573
China CN¥16.85 Billion
Bintulu Port Holdings Bhd
KLSE:5032
Malaysia RM1.33 Billion
Truecaller AB (publ)
ST:TRUE-B
Sweden Skr355.10 Million
Seche Environnem.
PA:SCHP
France €1.73 Billion
Weihai Guangtai Airport Equipment Co Ltd
SHE:002111
China CN¥3.43 Billion
Ningbo Runhe High-Tech Materials Co Ltd Class A
SHE:300727
China CN¥479.52 Million
Marine Electricals (India) Limited
NSE:MARINE
India Rs3.89 Billion

Liability Composition Analysis (2021–2024)

This chart breaks down Shandong Keyuan Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Shandong Keyuan Pharmaceutical Co. Ltd. .

Liquidity & Leverage Metrics

Shandong Keyuan Pharmaceutical Co. Ltd. A Total Liabilities Ratios Explained

Shandong Keyuan Pharmaceutical Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 6.55 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shandong Keyuan Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)

The table below shows the annual total liabilities of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥192.87 Million
≈ $28.22 Million
+38.83%
2023-12-31 CN¥138.93 Million
≈ $20.33 Million
+5.20%
2022-12-31 CN¥132.06 Million
≈ $19.32 Million
+2.75%
2021-12-31 CN¥128.52 Million
≈ $18.81 Million
--

About Shandong Keyuan Pharmaceutical Co. Ltd. A

SHE:301281 China Drug Manufacturers - General
Market Cap
$600.26 Million
CN¥4.10 Billion CNY
Market Cap Rank
#10953 Global
#2955 in China
Share Price
CN¥37.88
Change (1 day)
-4.25%
52-Week Range
CN¥26.26 - CN¥58.05
All Time High
CN¥59.70
About

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more